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the opportunity to evaluate several diagnostic workflow from a combined clinical 
and economic perspective using a cost-effectiveness analysis.
PCV9
An Assessment Of the Current LiterAture On APheresis use in the 
treAtment Of fAmiLiAL hyPerChOLesterOLemiA
Wang A.1, Richhariya A.2, Gandra S.R.2, Calimlim B.1, Kim L.1, Nordyke R.1
1ICON, El Segundo, CA, USA, 2Amgen, Inc., Thousand Oaks, CA, USA
Objectives: Although apheresis is an important treatment for reducing LDL-C in 
familial hypercholesterolemia (FH) patients, little is known about its treatment pat-
terns. We conducted a systematic review to assess the efficacy/effectiveness, prac-
tice patterns, cost, and clinical guidelines for apheresis in FH patients. MethOds: 
Electronic databases were searched for publications of apheresis in FH patients. 
Inclusion criteria include: articles in English published 2000-2013, description of 
practice patterns, efficacy/effectiveness, and costs. Data were stratified by country 
and FH genotype where possible. Results: Thirty-seven studies met the inclusion 
criteria: 8 open-label clinical trials, 11 observational studies, 16 reviews/guidelines, 
and 2 health technology assessments. Of the 19 clinical and observational studies, 
6 assessed only homozygous FH (HoFH) patients, 4 assessed only heterozygous FH 
(HeFH) patients, 6 included HoFH and HeFH patients, and 3 did not specify type of 
FH. The prevalence of FH is not well characterized by country and underdiagnosis 
is a barrier to optimal FH treatment. Apheresis guidelines recommend weekly/bi-
weekly treatments conducted at apheresis centers that may last ≥ 3 hours per ses-
sion. Apheresis may be recommended as first-line treatment in HoFH patients and 
after drug therapy failure in HeFH patients. Studies reported a range of LDL-C reduc-
tion after apheresis: HoFH: 57-75%; HeFH: 58-63%. Eight studies reported apheresis 
costs. Cost (USD 2013) per apheresis session ranged from $2,200-$4,300 in the US, 
$2,150-$2,600 in the UK, $1700-$1850 in Germany and France, and $2,350-$2,750 
in Australia. Calculated annual costs may reach $88,400-$225,000 per patient for 
weekly treatment. cOnclusiOns: LDL-C apheresis treatment is necessary for FH 
patients when drug therapy is inadequate. While apheresis reduces LDL-C, high 
per-session costs and the frequency of guideline-recommended treatment result 
in substantial annual costs. The costs and the inconvenience of apheresis sessions 
are barriers in optimal treatment of FH.
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Objectives: Our objective was to estimate the impact of catheter-based renal 
denervation plus standard of care (RDN) versus standard of care alone (SoC) on 
European stage-1 hypertension patients with different cardiovascular risk factor 
profiles. MethOds: We simulated resistant hypertension cohorts with different 
cardiovascular risk factor profiles (CVRPs) who had stage-1 hypertension despite 
adequate treatment with SoC. Six different cohorts with permutations of starting 
ages of 40, 55, or 70 years; and low and high CVRPs based on JNC7 guidelines were 
modeled. Interventions were RDN plus SoC with three or more anti-hypertensives 
including a diuretic at full doses or SoC alone. As observed in a recent prospective 
uncontrolled pilot study, the impact of a 13 mmHg reduction in systolic blood pres-
sure (SBP) – from a baseline SBP of 151 mmHg – was evaluated. Undiscounted life 
year (LY) and quality-adjusted life year (QALY) gain was computed using a published 
life-time Markov simulation model based on multivariate risk equations. Results: 
Across the studied age groups and cardiovascular risk profiles, catheter-based renal 
denervation was associated with gains in unadjusted (0.51-1.48 LYs) and quality-
adjusted life expectancy (0.39-1.20 QALYs). Younger age and higher cardiovascular 
risk profile led to numerically higher increments. The cohort-specific LY and QALY 
gains were projected as follows: 1) 40 year old cohorts: low CV risk profile: 0.84 LYs/ 
0.78 QALYs; high CV risk profile: 1.48 LYs/ 1.20 QALYs; 2) 55 year old cohorts: low CV 
risk profile: 0.69 LYs/ 0.60 QALYs; high CV risk profile: 1.29 LYs/ 0.95 QALYs; 3) 70 year 
old cohorts: low CV risk profile: 0.51 LYs/ 0.39 QALYs; high CV risk profile: 0.99 LYs/ 
0.68 QALYs. cOnclusiOns: RDN, when used to treat moderate treatment-resistant 
hypertension, is associated with clinically significant increases in life expectancy. 
These model-based findings need to be confirmed in clinical trials.
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Objectives: The objective of this review was to investigate the use of MIS and intra-
operative imaging technologies in the treatment and management of persons with 
ICH. MethOds: A systematic search of the published literature was undertaken in 
February 2014, using the Embase, PubMed and CRD York bibliographic databases. Key 
society websites were also searched for relevant ICH practice guidelines. Studies and 
guidelines reporting on MIS techniques in persons eligible for treatment for Primary 
ICH were included. Results: 1042 citations were retrieved, of which 190 full-text 
articles were reviewed. Six practice guidelines, 4 Systematic reviews, 10 RCTs and 3 
Economic evaluations were included. All 4 systematic reviews of RCT data showed 
consistent results in favour of MIS versus medical management (MM) or craniotomy 
(CR) for both efficacy (mortality and/ or mortality and dependent living benefit) and 
safety (lower rebleeding and higher hematoma volume reduction) vs. CR. A statisti-
cally significant reduction in the relative risk (RR) of death ranging from 34-71% for 
patients treated with MIS as opposed to CR or MM was reported in all 4 reviews. Three 
ICH guidelines (Europe, Japan and USA) recommended the use MIS in specific circum-
of atherothrombotic events (when combined with antiplatelet therapy) following an 
acute coronary syndrome. Use, safety and effectiveness of rivaroxaban in real-life 
settings need to be monitored to understand its value and comply with regulatory 
requirements. Objectives: To develop a pharmacoepidemiologic PASS programme 
to characterize post-authorization rivaroxaban use and relevant outcomes related to 
safety (intracranial, gastrointestinal, and urogenital haemorrhage) and effectiveness 
(myocardial infarction, ischaemic stroke and thromboembolic events). MethOds: 
European sources of longitudinal observational health care data were identified 
that contained population-based data on demographics, comorbidities and co-
medications. Additional studies were designed to capture drug utilization, safety 
and effectiveness data in primary and secondary care via physician questionnaire 
completed based on medical chart review. With an emphasis on the consistent 
definition of endpoints, protocols were developed and tailored for each study for 
submission to regulatory authorities and relevant ethics committees. Results: 
A PASS programme of 7 studies was designed. Rivaroxaban drug utilization, and 
safety and effectiveness, in comparison with standard of care, are being assessed 
using The Health Improvement Network (UK), the PHARMO Database Network (The 
Netherlands), the German Pharmacoepidemiological Research Database and the 
National Swedish Registries. The programme also includes 2 Specialist Cohort Event 
Monitoring studies to collect data on the initial treatment period in secondary care 
settings, and a complementary Modified Prescription-Event Monitoring study that 
evaluates long-term use in primary care. cOnclusiOns: This pharmacoepidemio-
logic PASS programme, with its unique and complementary approach, will monitor 
and characterize the real-life benefit–risk profile of rivaroxaban. A flexible design 
allows the accommodation of any new indications for rivaroxaban approved dur-
ing the study.
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Objectives: (1) To assess the prevalence of migraine using the National Health 
and Nutrition Examination Survey (NHANES) conducted in the general United 
States population; (2) To calculate the 10-year Framingham cardiovascular dis-
ease (CVD) and coronary heart disease (CHD) risks and compare the risks between 
migraine patients (MP) and non-migraineurs (NM). MethOds: MP were identi-
fied using the survey question: “During the past 3 months, did you have severe 
headaches or migraines?” from the 1999-2000, 2001-2002, and 2003-2004 NHANES. 
Independent chi-square tests and t-tests were used to compare differences in 
CVD or CHD risk factors between MP and NM. Multivariant ordinal logistic regres-
sions were used to examine the odds ratios of low, moderate, and high CHD and 
CVD risks between MP and NM accounting for the complex sampling design 
used by NHANES. Significance was defined as p≤ 0.05. Results: Amongst the 
total of 14,204 study subjects (6,731 men and 7,473 women), 2,895 (20.38%) sub-
jects reported having migraines or severe headaches in the past three months. 
The average age of MP was 41.8 (±16.8) years, compared to 47.4 (±19.8) years in 
the NM group. MP had a significantly higher percentage of females, with 1,962 
(67.77%) females. Subjects in the migraine group were found to have an odds 
ratio of 1.208 (95% CI, 1.033-1.412, p-value< 0.001) for moderate CHD risk, and 
an odds ratio of 0.975 (95% CI, 0.732 – 1.412, p-value< 0.001) for high CHD risk. 
Regarding CVD risk, migraine patients were found to have an odds ratio of 1.173 (95% 
CI, 0.818 – 1.683, p-value< 0.001) for moderate risk, and an odds ratio of 1.112 (95% CI, 
0.909 – 1.582, p-value< 0.001) for high risk. cOnclusiOns: Migraine appears to be 
more prevalent among younger subjects with an overall mean age of 42 years old. 
These findings also suggest a positive association between migraine and CHD risks.
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Objectives: The analysis of different non-invasive imaging strategies in a 
European population of patients with stable angina could help the identification 
of the best approach for the diagnosis of significant CAD. MethOds: In 475 pts 
(291 males, 60±9 yrs) with stable angina enrolled in the EVINCI multicenter study, 
CT coronary angiography (CTCA) and stress imaging were performed before inva-
sive coronary angiography (ICA). Significant CAD was defined as > 50% stenosis 
in the left main or > 70% stenosis in a major coronary vessel or 30-70% stenosis 
with fractional flow reserve ≤ 0.8. Nine non-invasive imaging strategies including 
CTCA or stress imaging (ECHO, CMR, SPECT or PET) alone or in combination with 
CTCA performed as first line examinations were evaluated. Combinations were 
positive if both CTCA and the stress test were positive and their performance 
was evaluated in terms of accuracy (AUC). Centres specific reimbursements were 
collected for invasive and non-invasive examination and the costs associated 
with different strategies were obtained at individual patient level by summing 
up reimbursement of the examinations involved. Results: Significant CAD was 
diagnosed at ICA in 140 patients (29%). CTCA had the highest diagnostic perfor-
mance among strategies involving single imaging modalities [0.91 (0.88-0.94)] and 
CTCA-PET among combinations [0.84 (0.74-0.93)]. Costs vary significantly among 
the strategies involving single non invasive modalities with value ranging from 
425 Euro for ECHO to 1245 Euro for PET as well as for those involving combina-
tions of imaging modalities ranging from 508 Euro for CTCA-ECHO to 870 Euro for 
CTCA-SPECT. cOnclusiOns: The diagnostic workflow for CAD detection shows 
variable effectiveness and costs according to the use of different single or com-
bined non invasive imaging modalities. Data collected in the EVINCI study offer 
